Mateo Aboy
Biographic Data
| ID | 9494628 |
|---|---|
| NAME | Mateo Aboy |
| GIVEN NAMES | Mateo |
| FAMILY NAME | Aboy |
| SIGNATURE | ABOY M |
| AFFILIATIONS | University of Cambridge |
| ORCID | 0000-0002-5168-4321 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
The Republic of Translational Medicine
Established pharmaceutical innovation theory holds that companies and patents are essential for developing new treatments. Yet, it does not adequately explain numerous clinical trials conducted by hospitals and universities. This paper introduces a new, complementary theory that describes a parallel system of innovation, focused on new uses of already authorised drugs, particularly once generics are available. These trials are driven by incentive…
Chat-IRB? How application-specific language models can enhance research ethics review
Institutional review boards (IRBs) play a crucial role in ensuring the ethical conduct of human subjects research, but face challenges including inconsistency, delays, and inefficiencies. We propose the development and implementation of application-specific large language models (LLMs) to facilitate IRB review processes. These IRB-specific LLMs would be fine-tuned on IRB-specific literature and institutional datasets, and equipped with retrieval …
No prominent works on this page.
Chat-IRB? How application-specific language models can enhance research ethics review
Institutional review boards (IRBs) play a crucial role in ensuring the ethical conduct of human subjects research, but face challenges including inconsistency, delays, and inefficiencies. We propose the development and implementation of application-specific large language models (LLMs) to facilitate IRB review processes. These IRB-specific LLMs would be fine-tuned on IRB-specific literature and institutional datasets, and equipped with retrieval …
The Republic of Translational Medicine
Established pharmaceutical innovation theory holds that companies and patents are essential for developing new treatments. Yet, it does not adequately explain numerous clinical trials conducted by hospitals and universities. This paper introduces a new, complementary theory that describes a parallel system of innovation, focused on new uses of already authorised drugs, particularly once generics are available. These trials are driven by incentive…
Alternative medicine (1 work) · Artificial Intelligence (1 work) · Artificial Intelligence in Healthcare and Education (1 work) · Biomedical Ethics and Regulation (1 work) · Clinical trial (1 work) · Computer Science (1 work) · Computer security (1 work) · Data science (1 work) · Engineering ethics (1 work) · Ethics and Social Impacts of AI (1 work)